Showing 26–42 of 42 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Shaki Aktar
The prevalence of tuberculosis (TB) is reducing in Bangladesh, but the emergence of drug resistant tuberculosis make the TB control effort more challenging and questionable. The present study aimed to identify the socio-demographic, behavioral and clinical risk factors for develo…
Brittney Sweetser, Esin Nkereuwem, Jascent Nakafeero, Marie Gomez, Peter Wambi, et al.
**BACKGROUND:** Children with non-severe TB may benefit from short-course treatment, but point-of-care tools are needed to stratify disease severity. We prospectively evaluated the Cepheid Xpert MTB-Host Response (HR) prototype cartridge for distinguishing TB severity in children…
Finlayson H, Lishman J, Palmer M
Purpose of review The current review identifies recent advances in the prevention, diagnosis, and treatment of childhood tuberculosis (TB) with a focus on the WHO's updated TB management guidelines released in 2022. Recent findings The COVID-19 pandemic negatively affected global…
Fry S, Barnabas S, Cotton MF
Purpose of review Although tuberculosis (TB) causes much morbidity and mortality in children, diagnosis and treatment remain challenging. Recently, children have gained increasing attention in research and clinical trials driving improved contact management, case identification a…
M R Marll, M Magee, N Glover, T Ngwanto, N Mofokeng, et al.
Abstract Rationale Approximately half of all tuberculosis (TB) survivors develop post-TB lung disease (PTLD), defined as persistent respiratory abnormalities despite a microbiological cure. Fibrosis, which typically presents as a restrictive ventilatory impairment on pulmonary fu…
John Metcalfe, MD, PhD, MPH
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB). This study compared a 3-month rifapentine (RPT)/clofazim…
Prince Malonda ma Ndungi, Blaise Idiamwana Kutokama, Bijou Masokolo Malamba, Dosithée Ngo-Bebe
Background Tuberculosis, the second deadliest infectious disease in the world after COVID-19, is caused by Mycobacterium tuberculosis. This bacterium most commonly affects the lungs. Economic and financial barriers can hinder access to healthcare services for the diagnosis and ma…
Chabala, Chishala
Children with HIV are highly susceptible to tuberculosis (TB) and often require concurrent antiretroviral treatment (ART) and antituberculosis therapy. However, rifamycins, the key drugs for TB treatment, significantly interact with many ART classes, necessitating adjustments to …
Vaidehi Mehta, Ramsha Ansari, Ira Shah
Mixed tuberculosis occurs with multiple clonally distinct mycobacterium tuberculosis strains in an individual. We present a 12-year-old girl with steroid-resistant nephrotic syndrome and drug-sensitive pulmonary tuberculosis (Xpert MTB/Rif) and preextensively drug-resistant tuber…
Anbesan Hoole, Ahsan Ilyas, Sunaina Munawar, Matthew Cant, Rizwan Hameed, et al.
Abstract Introduction While Post Tuberculous (TB) Bronchiectasis is the most common cause of Bronchiectasis in South Asia, there has been little research into its microbiology and clinical characteristics in Pakistan. This single centre retrospective cohort study at Bach Christia…
Malika Gabdullina, Saya Gazezova, Gulzhan Ayapova, Manar Smagul, Roberta Horth, et al.
Abstract Background The COVID-19 pandemic negatively influenced the availability of TB related services around the world, including detection, diagnosis and treatment. The purpose of this research is to assess the impact of the COVID-19 pandemic on TB treatment outcomes in Almaty…
M.J. Cavaco, Sofia Giusti Alves, L. Mateus, André Nunes, Ricardo Cordeiro, et al.
<b>Introduction:</b> Tuberculosis (TB) remains a major health problem, with extensive research on case detection and treatment outcome. However, little is known about what happens after treatment completion. In the First International Symposium on post-TB lung health (2020), the …
Muhammad Abdul Hadi
Background: The optimal doses of first-line drugs for treating drug-susceptible tuberculosis in children and adolescents are still uncertain.
 Aim: The purpose of this study was to determine whether children treated with recommended or increased doses of first-line drugs ach…
Nduagu Samuel Uchechukwu, ONYEAGWARA Ngozi Carol, Ogisi Festus Oritsemajemite, MBATA Godwin Chukwuemeka
Background: Pulmonary tuberculosis is a debilitating infectious disease that affects all age groups and sadly, a leading cause of death in developing countries particularly in sub-Saharan Africa. One major challenge facing the global efforts against tuberculosis is drug-resistanc…
O. Omosebi, Olanrewaju S.O., Adejumo O.A.
TB is perhaps the most important contagious disease in the world and the leading cause of mortality by an infectious disease. As a result, WHO declared that achieving the reduction in TB incidence rate for achievement of the 90-90-90 target of the END-TB strategy will be an illus…
Sang Chul Lee, Jae Kwang Lee, Jung Mo Lee, Seon Cheol Park, Chang Hoon Han
Abstract Background Political change regarding for exemption of co-payment for tuberculosis (TB) treatment was made in July 2016. We investigated the effect of the co-payment waiver on long-term treatment interruption and clinical outcomes among pulmonary TB patients in South Kor…
Flávia M. Sant ́Anna, Mariana Araújo‐Pereira, Carolina Arana Stanis Schmaltz, María B. Arriaga, Raquel de Vasconcellos Carvalhães de Oliveira, et al.
Standard anti-tuberculosis treatment is highly effective, but a great challenge is the management of adverse drug reactions (ADR). Our study aimed to characterize ADR according to type, severity and time of occurrence. A prospective tuberculosis (TB) cohort has been followed, fro…